StockData

Neuroone Medical Technologies vs Neuraxis

NMTC and NRXS side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NMTC and NRXS compare

Neuraxis is the larger company, worth 8.9 times as much as Neuroone Medical Technologies ($60.3M against $6.8M).

Neuroone Medical Technologies scores higher on the StockData Score (11 against 0 for Neuraxis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNMTCNRXS
Size and price
Market cap$6.8M$60.3M
Share price$0.745$4.80
Change, 1 year−81.7%104%
Change, 5 years−94.5%–
Beta (5Y)0.330.62
Employees1824
StockData Score
Total score11 (better)0
Valuation score3 (better)0
Growth score2 (better)0
Performance score1 (better)0
Health score5 (better)0
Dividend score00
Valuation
P/S0.7×–
P/B1.8×–
FCF yield−106%–
Fair value$3.52–
Margin of safety78.8%–
Growth
Revenue growth (TTM)42.8%–
Profitability
Gross margin55.6%–
Operating margin−83.4%–
Net margin−78.6%–
FCF margin−75.6%–
Return on equity−125%–
Return on invested capital−672%–
Financial health
Debt / equity0.00–
Current ratio2.84–
Altman Z-score−19.38–
Piotroski F-score6–
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions22.7%21.7%
Held by insiders85.4%39.9%
Insider net buying, 12 months$682K$1.4M (better)
Short interest, % of float15.6%6.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.